Evidence map›Paper›PMID 23834261›Full record

ArticleACS applied materials & interfaces2013

Synthesis of apolipoprotein B lipoparticles to deliver hydrophobic/amphiphilic materials.

Hsueh-Liang Chu, Tsai-Mu Cheng, Hung-Wei Chen, Fu-Hsuan Chou, Yu-Chuan Chang, Hsin-Yu Lin, Shih-Yi Liu, Yu-Chuan Liang, Ming-Hua Hsu, Dian-Shyeu Wu and 10 more

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Recent Development of LDL-Based Nanoparticles for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  2. Review
  3. Article
  4. Article
  5. Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hsueh-Liang ChuDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu 30050, Taiwan.
Tsai-Mu Cheng
Hung-Wei Chen
Fu-Hsuan Chou
Yu-Chuan Chang
Hsin-Yu Lin
Shih-Yi Liu
Yu-Chuan Liang
Ming-Hua Hsu
Dian-Shyeu Wu
Hsing-Yuan Li
Li-Ping Ho
Ping-Ching Wu
Fu-Rong Chen
Gong-Shen Chen
Dar-Bin Shieh
Chia-Seng Chang
Chia-Hao Su
Zemin Yao
Chia-Ching Chang

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

To develop a drug delivery system (DDS), it is critical to address challenging tasks such as the delivery of hydrophobic and amphiphilic compounds, cell uptake, and the metabolic fate of the drug delivery carrier. Low-density lipoprotein (LDL) has been acknowledged as the human serum transporter of natively abundant lipoparticles such as cholesterol, triacylglycerides, and lipids. Apolipoprotein B (apo B) is the only protein contained in LDL, and possesses a binding moiety for the LDL receptor that can be internalized and degraded naturally by the cell. Therefore, synthetic/reconstituting apoB lipoparticle (rABL) could be an excellent delivery carrier for hydrophobic or amphiphilic materials. Here, we synthesized rABL in vitro, using full-length apoB through a five-step solvent exchange method, and addressed its potential as a DDS. Our rABL exhibited good biocompatibility when evaluated with cytotoxicity and cell metabolic response assays, and was stable during storage in phosphate-buffered saline at 4 °C for several months. Furthermore, hydrophobic superparamagnetic iron oxide nanoparticles (SPIONPs) and the anticancer drug M4N (tetra-O-methyl nordihydroguaiaretic acid), used as an imaging enhancer and lipophilic drug model, respectively, were incorporated into the rABL, leading to the formation of SPIONPs- and M4N- containing rABL (SPIO@rABL and M4N@rABL, respectively). Fourier transform infrared spectroscopy suggested that rABL has a similar composition to that of LDL, and successfully incorporated SPIONPs or M4N. SPIO@rABL presented significant hepatic contrast enhancement in T2-weighted magnetic resonance imaging in BALB/c mice, suggesting its potential application as a medical imaging contrast agent. M4N@rABL could reduce the viability of the cancer cell line A549. Interestingly, we developed solution-phase high-resolution transmission electron microscopy to observe both LDL and SPIO@rABL in the liquid state. In summary, our LDL-based DDS, rABL, has significant potential as a novel DDS for hydrophobic and amphiphilic materials, with good cell internalization properties and metabolicity.

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic AgentsApolipoproteins BBiocompatible MaterialsCell Line, TumorChemistry, PharmaceuticalCholesterolFerric CompoundsHydrophobic and Hydrophilic InteractionsLipoproteinsMagneticsMaterials TestingMiceMice, Inbred BALB CMicroscopy, Electron, TransmissionAntineoplastic AgentsApolipoproteins BBiocompatible MaterialsCholesterolFerric Compoundsferric oxideLipoproteinsSurface-Active Agents

Identifiers

PMID23834261
PMCPMC3744920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.